Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes

References

• Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–579. doi:10.1016/j.cell.2016.02.063
   PubMed Web of Science ®Google Scholar
• Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96–104. doi:10.1016/j.mce.2019.03.001
   PubMed Web of Science ®Google Scholar
• Li X, Liao M, Shen R, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm. 2018;2018:7375294. doi:10.1155/2018/7375294
   PubMed Web of Science ®Google Scholar
• Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel player in metabolic diseases. Front Endocrinol (Lausanne). 2020;11:64. doi:10.3389/fendo.2020.00064
   PubMed Web of Science ®Google Scholar
• Groener JB, Valkanou A, Kender Z, et al. Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS One. 2019;14(9):e0222771. doi:10.1371/journal.pone.0222771
   PubMed Web of Science ®Google Scholar
• Ugur K, Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol. 2019;2019:2521096. doi:10.1155/2019/2521096
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–188. doi:10.1016/j.cca.2017.10.034
   PubMed Web of Science ®Google Scholar
• Wiecek M, Szymura J, Maciejczyk M, Kantorowicz M, Szygula Z. Acute anaerobic exercise affects the secretion of asprosin, irisin, and other cytokines - a comparison between sexes. Front Physiol. 2018;9:1782. doi:10.3389/fphys.2018.01782
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444–1453. doi:10.1038/nm.4432
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tan Y, Zhu L, et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci. 2019;231:116554. doi:10.1016/j.lfs.2019.116554
   PubMedGoogle Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–2883. doi:10.2337/dc14-1296
   PubMed Web of Science ®Google Scholar
• Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333–2340. doi:10.1172/JCI72271
   PubMed Web of Science ®Google Scholar
• Aghadavod E, Khodadadi S, Baradaran A, Nasri P, Bahmani M, Rafieian-Kopaei M. Role of oxidative stress and inflammatory factors in diabetic kidney disease. Iran J Kidney Dis. 2016;10(6):337–343.
   PubMed Web of Science ®Google Scholar
• Gnudi L, Coward RJM, Long DA. Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27(11):820–830. doi:10.1016/j.tem.2016.07.002
   PubMed Web of Science ®Google Scholar
• Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(8):1366–1373. doi:10.2215/CJN.11111016
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi:10.2215/cjn.11491116
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157–1165. doi:10.2337/diabetes.51.4.1157
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–1821. doi:10.1681/ASN.2008121270
   PubMed Web of Science ®Google Scholar
• Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316(6):602–610. doi:10.1001/jama.2016.10924
   PubMed Web of Science ®Google Scholar
• El Kattawy HA, Ashour WM. Anti-asprosin: a potential protective role against the progression of diabetic nephropathy in type 2 diabetic rats. Am J Biomed Sci. 2019;11(3).
   Google Scholar
• American Diabetes A. (2) classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl):S8–S16. doi:10.2337/dc15-S005
   Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/ASN.2006040368
   PubMed Web of Science ®Google Scholar
• Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J, Bastard JP. How can we measure insulin sensitivity/resistance? Diabetes Metab. 2011;37(3):179–188. doi:10.1016/j.diabet.2011.01.002
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006;21(9):2366–2374. doi:10.1093/ndt/gfl309
   PubMedGoogle Scholar
• Zhang H, Hu W, Zhang G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int Urol Nephrol. 2020;52(8):1517–1522. doi:10.1007/s11255-020-02509-8
   PubMed Web of Science ®Google Scholar
• Toyama T, Shimizu M, Furuichi K, Kaneko S, Wada T. Treatment and impact of dyslipidemia in diabetic nephropathy. Clin Exp Nephrol. 2014;18(2):201–205. doi:10.1007/s10157-013-0898-1
   PubMedGoogle Scholar
• Bonacina F, Baragetti A, Catapano AL, Norata GD. The interconnection between immuno-metabolism, diabetes, and CKD. Curr Diab Rep. 2019;19(5):21. doi:10.1007/s11892-019-1143-4
   PubMedGoogle Scholar
• Zhang Y, Ma KL, Liu J, et al. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol. 2015;52(6):1045–1056. doi:10.1007/s00592-015-0753-9
   PubMed Web of Science ®Google Scholar
• Lieben L. Diabetic nephropathy: lipid toxicity drives renal disease. Nat Rev Nephrol. 2017;13(4):194. doi:10.1038/nrneph.2017.22
   PubMedGoogle Scholar
• Yuan Y, Sun H, Sun Z. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN). Lipids Health Dis. 2017;16(1):126. doi:10.1186/s12944-017-0522-6
   PubMedGoogle Scholar
• Ng KF, Aung HH, Rutledge JC. Role of triglyceride-rich lipoproteins in renal injury. Contrib Nephrol. 2011;170:165–171. doi:10.1159/000325654
   PubMedGoogle Scholar
• Islam N, Kazmi F, Chusney GD, Mattock MB, Zaini A, Pickup JC. Ethnic differences in correlates of microalbuminuria in NIDDM. The role of the acute-phase response. Diabetes Care. 1998;21(3):385–388. doi:10.2337/diacare.21.3.385
   PubMedGoogle Scholar
• Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol. 2014;18(2):206–209. doi:10.1007/s10157-013-0880-y
   PubMed Web of Science ®Google Scholar
• Wei W, An XR, Jin SJ, Li XX, Xu M. Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy. Sci Rep. 2018;8(1):9. doi:10.1038/s41598-017-18427-2
   PubMedGoogle Scholar
• Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583. doi:10.1155/2018/9471583
   PubMed Web of Science ®Google Scholar
• Alan M, Gurlek B, Yilmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):220–223. doi:10.1080/09513590.2018.1512967
   PubMed Web of Science ®Google Scholar
• Jung TW, Kim HC, Kim HU, et al. Asprosin attenuates insulin signaling pathway through PKCdelta-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234(11):20888–20899. doi:10.1002/jcp.28694
   PubMed Web of Science ®Google Scholar